A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it sho...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2020-11, Vol.11 (47), p.4457-4462
Main Authors: de Velasco, Guillermo, Carril-Ajuria, Lucia, Guerrero-Ramos, Felix, Alonso-Gordoa, Teresa, Rodríguez-Moreno, Juan F, Carretero, Alberto, Martin-Soberon, Maricruz, de la Rosa-Kehrmann, Federico, Castellano, Daniel
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment. This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.27807